www.jhoonline.org

Table 1
A summary of clinical trials with angiogenesis inhibitors in prostate cancer.
Drug(s)		N	Population	Clinical benefit	Ref

VEGF monoclonal antibody
Bevacizumab 10 mg/kg q2wk × 6	Ph II	15	mCRPC	4 of 15 had PSA decline < 50% No PSA decline > 50% No objective responses	[30]
Bevacizumab 15 mg/kg d2 Docetaxel 70 mg/m2 q3wk Estramustine 280 mg TID d1-5	PhII	79	mCRPC	PSA response > 50% in 77% of patients 42% with radiographic partial response	[32,33]
Bevacizumab 10 mg/kg q3wk Docetaxel 60 mg/m2	PhII	20	mCRPC, docetaxel failure	PSA response > 50% in 55% of patients 3 of 8 patients had objective radiographic response	[34]

Tyrosine Kinase Inhibitor
Sorafenib 400 mg BID	PhII	22	mCRPC,	No PSA decline > 50% No objective radiographic responses	[36]
Sorafenib 400 mg BID	PhII	28	CRPC, docetaxel-naïve	PSA response > 50% in 1 patient (3.6%) No objective radiographic responses	[37]
Sorafenib 400 mg BID	PhII	55	CRPC, docetaxel-naïve	PSA response > 50% in 2 patients (3.6%) No objective radiographic responses	[38]
Sunitinib 50 mg/day × 4 wks of 6 wk cycle	PhII	34	CRPC	PSA response > 50% in 2 patients (5.9%) 1 objective radiographic response (2.9%)	[40]

Thalidomide
Thalidomide 200 mg/day	PhII	63	CRPC	PSA response > 50% in 14% of patients No objective radiographic responses	[43]
Thalidomide 200 mg/day	PhIII	159	bCSPC	Crossover design, time to restarting intermittent ADT Time to PSA progression favored thalidomide group 15 v 9.6 mo, p = 0.21 in first phase 17.1 v 6.6 mo, p = 0002 in second phase	[45]
Thalidomide 200 mg/day Docetaxel 30 mg/m2 d1, 8, 15 of 28 day cycle	rPhII	75	mCRPC, docetaxel-naïve	PSA response > 50% in 53% of thalidomide group vs PSA response > 50% in 37% of control group (p = 0.32) OS of 25.9 mo in thalidomide group vs OS of 14.7 mo in control group (p = 0.0407)	[46-48]
Thalidomide 200 mg/day Docetaxel 30 mg/m2 d1, 8, 15 Estramustine TID d1-3, 8-10, 15-17 of 28 day cycle	PhII	20	mCRPC, docetaxel-naïve	PSA response > 50% in 90% of patients	[49]
Thalidomide 200 mg/day Docetaxel 75 mg/m2 q3wk Bevacizumab 15 mg/kg q3wk	PhII	60	mCRPC, docetaxel-naïve	PSA response > 50% in 88% of patients	[50]

Pending Phase III studies
Docetaxel + Prednisone +/- Bevacizumab	PhIII	1050	mCRPC, docetaxel-naïve	Preliminary results indicate no benefit in overall survival for bevacizumab arm	[35]
Docetaxel + Prednisone +/- Lenalidomide	PhIII	1015*	mCRPC, docetaxel-naïve	Results pending	NCT00988208
Prednisone +/- Sunitinib	PhIII	819*	mCRPC, docetaxel failure	Results pending	NCT00676650

*Anticipated Enrollment. mCRPC - metastatic castrate-resistant Prostate Cancer. bCRPC - biochemically recurrent castrate-resistant prostate cancer. bCSPC - biochemically recurrent castrate-sensitive prostate cancer.
Hwang and Heath Journal of Hematology & Oncology 2010 3:26 doi:10.1186/1756-8722-3-26

Table 1